VKTX vs. PRTA, ICPT, PBYI, MRNS, ALNY, GMAB, TEVA, RPRX, BMRN, and BGNE
Should you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Prothena (PRTA), Intercept Pharmaceuticals (ICPT), Puma Biotechnology (PBYI), Marinus Pharmaceuticals (MRNS), Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), Teva Pharmaceutical Industries (TEVA), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), and BeiGene (BGNE).
Prothena (NASDAQ:PRTA) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.
Prothena has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.
Prothena presently has a consensus price target of $67.00, suggesting a potential upside of 217.08%. Viking Therapeutics has a consensus price target of $112.38, suggesting a potential upside of 100.71%. Given Viking Therapeutics' higher probable upside, research analysts plainly believe Prothena is more favorable than Viking Therapeutics.
97.1% of Prothena shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 28.1% of Prothena shares are owned by insiders. Comparatively, 4.7% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Viking Therapeutics has a net margin of 0.00% compared to Viking Therapeutics' net margin of -193.17%. Prothena's return on equity of -18.41% beat Viking Therapeutics' return on equity.
Viking Therapeutics received 2 more outperform votes than Prothena when rated by MarketBeat users. Likewise, 79.84% of users gave Viking Therapeutics an outperform vote while only 70.67% of users gave Prothena an outperform vote.
In the previous week, Viking Therapeutics had 17 more articles in the media than Prothena. MarketBeat recorded 21 mentions for Viking Therapeutics and 4 mentions for Prothena. Prothena's average media sentiment score of 0.67 beat Viking Therapeutics' score of 0.43 indicating that Viking Therapeutics is being referred to more favorably in the news media.
Viking Therapeutics has lower revenue, but higher earnings than Prothena. Viking Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.
Summary
Viking Therapeutics beats Prothena on 13 of the 18 factors compared between the two stocks.
Get Viking Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viking Therapeutics Competitors List
Related Companies and Tools
